line_item,period,value,symbol
Tax Effect Of Unusual Items,2025-03-31 00:00:00,0.0,PPLPHARMA.NS
Tax Rate For Calcs,2025-03-31 00:00:00,0.3,PPLPHARMA.NS
Normalized EBITDA,2025-03-31 00:00:00,16525700000.0,PPLPHARMA.NS
Total Unusual Items,2025-03-31 00:00:00,0.0,PPLPHARMA.NS
Total Unusual Items Excluding Goodwill,2025-03-31 00:00:00,0.0,PPLPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2025-03-31 00:00:00,911300000.0,PPLPHARMA.NS
Reconciled Depreciation,2025-03-31 00:00:00,8163400000.0,PPLPHARMA.NS
Reconciled Cost Of Revenue,2025-03-31 00:00:00,32316500000.0,PPLPHARMA.NS
EBITDA,2025-03-31 00:00:00,16525700000.0,PPLPHARMA.NS
EBIT,2025-03-31 00:00:00,8362300000.0,PPLPHARMA.NS
Net Interest Income,2025-03-31 00:00:00,-4215900000.0,PPLPHARMA.NS
Interest Expense,2025-03-31 00:00:00,4215900000.0,PPLPHARMA.NS
Interest Income,2025-03-31 00:00:00,,PPLPHARMA.NS
Normalized Income,2025-03-31 00:00:00,911300000.0,PPLPHARMA.NS
Net Income From Continuing And Discontinued Operation,2025-03-31 00:00:00,911300000.0,PPLPHARMA.NS
Total Expenses,2025-03-31 00:00:00,85226900000.0,PPLPHARMA.NS
Rent Expense Supplemental,2025-03-31 00:00:00,,PPLPHARMA.NS
Diluted Average Shares,2025-03-31 00:00:00,1340147059.0,PPLPHARMA.NS
Basic Average Shares,2025-03-31 00:00:00,1320724638.0,PPLPHARMA.NS
Diluted EPS,2025-03-31 00:00:00,0.68,PPLPHARMA.NS
Basic EPS,2025-03-31 00:00:00,0.69,PPLPHARMA.NS
Diluted NI Availto Com Stockholders,2025-03-31 00:00:00,911300000.0,PPLPHARMA.NS
Net Income Common Stockholders,2025-03-31 00:00:00,911300000.0,PPLPHARMA.NS
Otherunder Preferred Stock Dividend,2025-03-31 00:00:00,0.0,PPLPHARMA.NS
Net Income,2025-03-31 00:00:00,911300000.0,PPLPHARMA.NS
Minority Interests,2025-03-31 00:00:00,0.0,PPLPHARMA.NS
Net Income Including Noncontrolling Interests,2025-03-31 00:00:00,911300000.0,PPLPHARMA.NS
Net Income Continuous Operations,2025-03-31 00:00:00,911300000.0,PPLPHARMA.NS
Tax Provision,2025-03-31 00:00:00,3235100000.0,PPLPHARMA.NS
Pretax Income,2025-03-31 00:00:00,4146400000.0,PPLPHARMA.NS
Other Non Operating Income Expenses,2025-03-31 00:00:00,1348100000.0,PPLPHARMA.NS
Special Income Charges,2025-03-31 00:00:00,0.0,PPLPHARMA.NS
Other Special Charges,2025-03-31 00:00:00,,PPLPHARMA.NS
Write Off,2025-03-31 00:00:00,,PPLPHARMA.NS
Impairment Of Capital Assets,2025-03-31 00:00:00,,PPLPHARMA.NS
Restructuring And Mergern Acquisition,2025-03-31 00:00:00,,PPLPHARMA.NS
Net Non Operating Interest Income Expense,2025-03-31 00:00:00,-4215900000.0,PPLPHARMA.NS
Total Other Finance Cost,2025-03-31 00:00:00,,PPLPHARMA.NS
Interest Expense Non Operating,2025-03-31 00:00:00,4215900000.0,PPLPHARMA.NS
Interest Income Non Operating,2025-03-31 00:00:00,,PPLPHARMA.NS
Operating Income,2025-03-31 00:00:00,6284900000.0,PPLPHARMA.NS
Operating Expense,2025-03-31 00:00:00,52910400000.0,PPLPHARMA.NS
Other Operating Expenses,2025-03-31 00:00:00,21672300000.0,PPLPHARMA.NS
Depreciation And Amortization In Income Statement,2025-03-31 00:00:00,8163400000.0,PPLPHARMA.NS
Depreciation Income Statement,2025-03-31 00:00:00,8163400000.0,PPLPHARMA.NS
Research And Development,2025-03-31 00:00:00,,PPLPHARMA.NS
Selling General And Administration,2025-03-31 00:00:00,,PPLPHARMA.NS
Selling And Marketing Expense,2025-03-31 00:00:00,,PPLPHARMA.NS
General And Administrative Expense,2025-03-31 00:00:00,,PPLPHARMA.NS
Rent And Landing Fees,2025-03-31 00:00:00,,PPLPHARMA.NS
Gross Profit,2025-03-31 00:00:00,59195300000.0,PPLPHARMA.NS
Cost Of Revenue,2025-03-31 00:00:00,32316500000.0,PPLPHARMA.NS
Total Revenue,2025-03-31 00:00:00,91511800000.0,PPLPHARMA.NS
Operating Revenue,2025-03-31 00:00:00,91511800000.0,PPLPHARMA.NS
Tax Effect Of Unusual Items,2024-03-31 00:00:00,-188370000.0,PPLPHARMA.NS
Tax Rate For Calcs,2024-03-31 00:00:00,0.3,PPLPHARMA.NS
Normalized EBITDA,2024-03-31 00:00:00,14311400000.0,PPLPHARMA.NS
Total Unusual Items,2024-03-31 00:00:00,-627900000.0,PPLPHARMA.NS
Total Unusual Items Excluding Goodwill,2024-03-31 00:00:00,-627900000.0,PPLPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2024-03-31 00:00:00,178200000.0,PPLPHARMA.NS
Reconciled Depreciation,2024-03-31 00:00:00,7405600000.0,PPLPHARMA.NS
Reconciled Cost Of Revenue,2024-03-31 00:00:00,29540000000.0,PPLPHARMA.NS
EBITDA,2024-03-31 00:00:00,13683500000.0,PPLPHARMA.NS
EBIT,2024-03-31 00:00:00,6277800000.0,PPLPHARMA.NS
Net Interest Income,2024-03-31 00:00:00,-4484900000.0,PPLPHARMA.NS
Interest Expense,2024-03-31 00:00:00,4484900000.0,PPLPHARMA.NS
Interest Income,2024-03-31 00:00:00,119200000.0,PPLPHARMA.NS
Normalized Income,2024-03-31 00:00:00,617730000.0,PPLPHARMA.NS
Net Income From Continuing And Discontinued Operation,2024-03-31 00:00:00,178200000.0,PPLPHARMA.NS
Total Expenses,2024-03-31 00:00:00,77154700000.0,PPLPHARMA.NS
Rent Expense Supplemental,2024-03-31 00:00:00,315900000.0,PPLPHARMA.NS
Diluted Average Shares,2024-03-31 00:00:00,1272857143.0,PPLPHARMA.NS
Basic Average Shares,2024-03-31 00:00:00,1272857143.0,PPLPHARMA.NS
Diluted EPS,2024-03-31 00:00:00,0.14,PPLPHARMA.NS
Basic EPS,2024-03-31 00:00:00,0.14,PPLPHARMA.NS
Diluted NI Availto Com Stockholders,2024-03-31 00:00:00,178200000.0,PPLPHARMA.NS
Net Income Common Stockholders,2024-03-31 00:00:00,178200000.0,PPLPHARMA.NS
Otherunder Preferred Stock Dividend,2024-03-31 00:00:00,0.0,PPLPHARMA.NS
Net Income,2024-03-31 00:00:00,178200000.0,PPLPHARMA.NS
Minority Interests,2024-03-31 00:00:00,0.0,PPLPHARMA.NS
Net Income Including Noncontrolling Interests,2024-03-31 00:00:00,178200000.0,PPLPHARMA.NS
Net Income Continuous Operations,2024-03-31 00:00:00,178200000.0,PPLPHARMA.NS
Tax Provision,2024-03-31 00:00:00,1614700000.0,PPLPHARMA.NS
Pretax Income,2024-03-31 00:00:00,1792900000.0,PPLPHARMA.NS
Other Non Operating Income Expenses,2024-03-31 00:00:00,1753900000.0,PPLPHARMA.NS
Special Income Charges,2024-03-31 00:00:00,-627900000.0,PPLPHARMA.NS
Other Special Charges,2024-03-31 00:00:00,627900000.0,PPLPHARMA.NS
Write Off,2024-03-31 00:00:00,5800000.0,PPLPHARMA.NS
Impairment Of Capital Assets,2024-03-31 00:00:00,,PPLPHARMA.NS
Restructuring And Mergern Acquisition,2024-03-31 00:00:00,0.0,PPLPHARMA.NS
Net Non Operating Interest Income Expense,2024-03-31 00:00:00,-4484900000.0,PPLPHARMA.NS
Total Other Finance Cost,2024-03-31 00:00:00,15400000.0,PPLPHARMA.NS
Interest Expense Non Operating,2024-03-31 00:00:00,4484900000.0,PPLPHARMA.NS
Interest Income Non Operating,2024-03-31 00:00:00,119200000.0,PPLPHARMA.NS
Operating Income,2024-03-31 00:00:00,4556900000.0,PPLPHARMA.NS
Operating Expense,2024-03-31 00:00:00,47614700000.0,PPLPHARMA.NS
Other Operating Expenses,2024-03-31 00:00:00,19914000000.0,PPLPHARMA.NS
Depreciation And Amortization In Income Statement,2024-03-31 00:00:00,7405700000.0,PPLPHARMA.NS
Depreciation Income Statement,2024-03-31 00:00:00,7405700000.0,PPLPHARMA.NS
Research And Development,2024-03-31 00:00:00,1006700000.0,PPLPHARMA.NS
Selling General And Administration,2024-03-31 00:00:00,5668800000.0,PPLPHARMA.NS
Selling And Marketing Expense,2024-03-31 00:00:00,3041300000.0,PPLPHARMA.NS
General And Administrative Expense,2024-03-31 00:00:00,2627500000.0,PPLPHARMA.NS
Rent And Landing Fees,2024-03-31 00:00:00,315900000.0,PPLPHARMA.NS
Gross Profit,2024-03-31 00:00:00,52171600000.0,PPLPHARMA.NS
Cost Of Revenue,2024-03-31 00:00:00,29540000000.0,PPLPHARMA.NS
Total Revenue,2024-03-31 00:00:00,81711600000.0,PPLPHARMA.NS
Operating Revenue,2024-03-31 00:00:00,81711600000.0,PPLPHARMA.NS
Tax Effect Of Unusual Items,2023-03-31 00:00:00,-14640000.0,PPLPHARMA.NS
Tax Rate For Calcs,2023-03-31 00:00:00,0.3,PPLPHARMA.NS
Normalized EBITDA,2023-03-31 00:00:00,8991300000.0,PPLPHARMA.NS
Total Unusual Items,2023-03-31 00:00:00,-48800000.0,PPLPHARMA.NS
Total Unusual Items Excluding Goodwill,2023-03-31 00:00:00,-48800000.0,PPLPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2023-03-31 00:00:00,-1864600000.0,PPLPHARMA.NS
Reconciled Depreciation,2023-03-31 00:00:00,6766900000.0,PPLPHARMA.NS
Reconciled Cost Of Revenue,2023-03-31 00:00:00,30001800000.0,PPLPHARMA.NS
EBITDA,2023-03-31 00:00:00,8942500000.0,PPLPHARMA.NS
EBIT,2023-03-31 00:00:00,2175600000.0,PPLPHARMA.NS
Net Interest Income,2023-03-31 00:00:00,-3425400000.0,PPLPHARMA.NS
Interest Expense,2023-03-31 00:00:00,3377100000.0,PPLPHARMA.NS
Interest Income,2023-03-31 00:00:00,16400000.0,PPLPHARMA.NS
Normalized Income,2023-03-31 00:00:00,-1830440000.0,PPLPHARMA.NS
Net Income From Continuing And Discontinued Operation,2023-03-31 00:00:00,-1864600000.0,PPLPHARMA.NS
Total Expenses,2023-03-31 00:00:00,70803800000.0,PPLPHARMA.NS
Rent Expense Supplemental,2023-03-31 00:00:00,321000000.0,PPLPHARMA.NS
Diluted Average Shares,2023-03-31 00:00:00,1212672645.0,PPLPHARMA.NS
Basic Average Shares,2023-03-31 00:00:00,1212672645.0,PPLPHARMA.NS
Diluted EPS,2023-03-31 00:00:00,-1.54,PPLPHARMA.NS
Basic EPS,2023-03-31 00:00:00,-1.54,PPLPHARMA.NS
Diluted NI Availto Com Stockholders,2023-03-31 00:00:00,-1864600000.0,PPLPHARMA.NS
Net Income Common Stockholders,2023-03-31 00:00:00,-1864600000.0,PPLPHARMA.NS
Otherunder Preferred Stock Dividend,2023-03-31 00:00:00,0.0,PPLPHARMA.NS
Net Income,2023-03-31 00:00:00,-1864600000.0,PPLPHARMA.NS
Minority Interests,2023-03-31 00:00:00,,PPLPHARMA.NS
Net Income Including Noncontrolling Interests,2023-03-31 00:00:00,-1864600000.0,PPLPHARMA.NS
Net Income Continuous Operations,2023-03-31 00:00:00,-1864600000.0,PPLPHARMA.NS
Tax Provision,2023-03-31 00:00:00,663100000.0,PPLPHARMA.NS
Pretax Income,2023-03-31 00:00:00,-1201500000.0,PPLPHARMA.NS
Other Non Operating Income Expenses,2023-03-31 00:00:00,1101400000.0,PPLPHARMA.NS
Special Income Charges,2023-03-31 00:00:00,-74400000.0,PPLPHARMA.NS
Other Special Charges,2023-03-31 00:00:00,4800000.0,PPLPHARMA.NS
Write Off,2023-03-31 00:00:00,0.0,PPLPHARMA.NS
Impairment Of Capital Assets,2023-03-31 00:00:00,,PPLPHARMA.NS
Restructuring And Mergern Acquisition,2023-03-31 00:00:00,69600000.0,PPLPHARMA.NS
Net Non Operating Interest Income Expense,2023-03-31 00:00:00,-3425400000.0,PPLPHARMA.NS
Total Other Finance Cost,2023-03-31 00:00:00,64700000.0,PPLPHARMA.NS
Interest Expense Non Operating,2023-03-31 00:00:00,3377100000.0,PPLPHARMA.NS
Interest Income Non Operating,2023-03-31 00:00:00,16400000.0,PPLPHARMA.NS
Operating Income,2023-03-31 00:00:00,-479700000.0,PPLPHARMA.NS
Operating Expense,2023-03-31 00:00:00,40802000000.0,PPLPHARMA.NS
Other Operating Expenses,2023-03-31 00:00:00,8804400000.0,PPLPHARMA.NS
Depreciation And Amortization In Income Statement,2023-03-31 00:00:00,6766900000.0,PPLPHARMA.NS
Depreciation Income Statement,2023-03-31 00:00:00,6766900000.0,PPLPHARMA.NS
Research And Development,2023-03-31 00:00:00,863600000.0,PPLPHARMA.NS
Selling General And Administration,2023-03-31 00:00:00,5553800000.0,PPLPHARMA.NS
Selling And Marketing Expense,2023-03-31 00:00:00,3236900000.0,PPLPHARMA.NS
General And Administrative Expense,2023-03-31 00:00:00,2316900000.0,PPLPHARMA.NS
Rent And Landing Fees,2023-03-31 00:00:00,321000000.0,PPLPHARMA.NS
Gross Profit,2023-03-31 00:00:00,40322300000.0,PPLPHARMA.NS
Cost Of Revenue,2023-03-31 00:00:00,30001800000.0,PPLPHARMA.NS
Total Revenue,2023-03-31 00:00:00,70324100000.0,PPLPHARMA.NS
Operating Revenue,2023-03-31 00:00:00,70324100000.0,PPLPHARMA.NS
Tax Effect Of Unusual Items,2022-03-31 00:00:00,14274341.209947,PPLPHARMA.NS
Tax Rate For Calcs,2022-03-31 00:00:00,0.224793,PPLPHARMA.NS
Normalized EBITDA,2022-03-31 00:00:00,12535900000.0,PPLPHARMA.NS
Total Unusual Items,2022-03-31 00:00:00,63500000.0,PPLPHARMA.NS
Total Unusual Items Excluding Goodwill,2022-03-31 00:00:00,63500000.0,PPLPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2022-03-31 00:00:00,3759600000.0,PPLPHARMA.NS
Reconciled Depreciation,2022-03-31 00:00:00,5861800000.0,PPLPHARMA.NS
Reconciled Cost Of Revenue,2022-03-31 00:00:00,26803100000.0,PPLPHARMA.NS
EBITDA,2022-03-31 00:00:00,12599400000.0,PPLPHARMA.NS
EBIT,2022-03-31 00:00:00,6737600000.0,PPLPHARMA.NS
Net Interest Income,2022-03-31 00:00:00,-1975700000.0,PPLPHARMA.NS
Interest Expense,2022-03-31 00:00:00,1887800000.0,PPLPHARMA.NS
Interest Income,2022-03-31 00:00:00,6800000.0,PPLPHARMA.NS
Normalized Income,2022-03-31 00:00:00,3710374341.209947,PPLPHARMA.NS
Net Income From Continuing And Discontinued Operation,2022-03-31 00:00:00,3759600000.0,PPLPHARMA.NS
Total Expenses,2022-03-31 00:00:00,61063400000.0,PPLPHARMA.NS
Rent Expense Supplemental,2022-03-31 00:00:00,282500000.0,PPLPHARMA.NS
Diluted Average Shares,2022-03-31 00:00:00,1216975687.0,PPLPHARMA.NS
Basic Average Shares,2022-03-31 00:00:00,1216975687.0,PPLPHARMA.NS
Diluted EPS,2022-03-31 00:00:00,3.089298,PPLPHARMA.NS
Basic EPS,2022-03-31 00:00:00,3.089298,PPLPHARMA.NS
Diluted NI Availto Com Stockholders,2022-03-31 00:00:00,3759600000.0,PPLPHARMA.NS
Net Income Common Stockholders,2022-03-31 00:00:00,3759600000.0,PPLPHARMA.NS
Otherunder Preferred Stock Dividend,2022-03-31 00:00:00,0.0,PPLPHARMA.NS
Net Income,2022-03-31 00:00:00,3759600000.0,PPLPHARMA.NS
Minority Interests,2022-03-31 00:00:00,,PPLPHARMA.NS
Net Income Including Noncontrolling Interests,2022-03-31 00:00:00,3759600000.0,PPLPHARMA.NS
Net Income Continuous Operations,2022-03-31 00:00:00,3759600000.0,PPLPHARMA.NS
Tax Provision,2022-03-31 00:00:00,1090200000.0,PPLPHARMA.NS
Pretax Income,2022-03-31 00:00:00,4849800000.0,PPLPHARMA.NS
Other Non Operating Income Expenses,2022-03-31 00:00:00,2351200000.0,PPLPHARMA.NS
Special Income Charges,2022-03-31 00:00:00,-167800000.0,PPLPHARMA.NS
Other Special Charges,2022-03-31 00:00:00,5400000.0,PPLPHARMA.NS
Write Off,2022-03-31 00:00:00,11600000.0,PPLPHARMA.NS
Impairment Of Capital Assets,2022-03-31 00:00:00,0.0,PPLPHARMA.NS
Restructuring And Mergern Acquisition,2022-03-31 00:00:00,150800000.0,PPLPHARMA.NS
Net Non Operating Interest Income Expense,2022-03-31 00:00:00,-1975700000.0,PPLPHARMA.NS
Total Other Finance Cost,2022-03-31 00:00:00,94700000.0,PPLPHARMA.NS
Interest Expense Non Operating,2022-03-31 00:00:00,1887800000.0,PPLPHARMA.NS
Interest Income Non Operating,2022-03-31 00:00:00,6800000.0,PPLPHARMA.NS
Operating Income,2022-03-31 00:00:00,3651600000.0,PPLPHARMA.NS
Operating Expense,2022-03-31 00:00:00,34260300000.0,PPLPHARMA.NS
Other Operating Expenses,2022-03-31 00:00:00,7041600000.0,PPLPHARMA.NS
Depreciation And Amortization In Income Statement,2022-03-31 00:00:00,5861800000.0,PPLPHARMA.NS
Depreciation Income Statement,2022-03-31 00:00:00,5861800000.0,PPLPHARMA.NS
Research And Development,2022-03-31 00:00:00,1283400000.0,PPLPHARMA.NS
Selling General And Administration,2022-03-31 00:00:00,4768300000.0,PPLPHARMA.NS
Selling And Marketing Expense,2022-03-31 00:00:00,2856200000.0,PPLPHARMA.NS
General And Administrative Expense,2022-03-31 00:00:00,1912100000.0,PPLPHARMA.NS
Rent And Landing Fees,2022-03-31 00:00:00,282500000.0,PPLPHARMA.NS
Gross Profit,2022-03-31 00:00:00,37911900000.0,PPLPHARMA.NS
Cost Of Revenue,2022-03-31 00:00:00,26803100000.0,PPLPHARMA.NS
Total Revenue,2022-03-31 00:00:00,64715000000.0,PPLPHARMA.NS
Operating Revenue,2022-03-31 00:00:00,64715000000.0,PPLPHARMA.NS
Tax Effect Of Unusual Items,2021-03-31 00:00:00,,PPLPHARMA.NS
Tax Rate For Calcs,2021-03-31 00:00:00,,PPLPHARMA.NS
Normalized EBITDA,2021-03-31 00:00:00,,PPLPHARMA.NS
Total Unusual Items,2021-03-31 00:00:00,,PPLPHARMA.NS
Total Unusual Items Excluding Goodwill,2021-03-31 00:00:00,,PPLPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2021-03-31 00:00:00,,PPLPHARMA.NS
Reconciled Depreciation,2021-03-31 00:00:00,,PPLPHARMA.NS
Reconciled Cost Of Revenue,2021-03-31 00:00:00,,PPLPHARMA.NS
EBITDA,2021-03-31 00:00:00,,PPLPHARMA.NS
EBIT,2021-03-31 00:00:00,,PPLPHARMA.NS
Net Interest Income,2021-03-31 00:00:00,,PPLPHARMA.NS
Interest Expense,2021-03-31 00:00:00,,PPLPHARMA.NS
Interest Income,2021-03-31 00:00:00,207000000.0,PPLPHARMA.NS
Normalized Income,2021-03-31 00:00:00,,PPLPHARMA.NS
Net Income From Continuing And Discontinued Operation,2021-03-31 00:00:00,,PPLPHARMA.NS
Total Expenses,2021-03-31 00:00:00,,PPLPHARMA.NS
Rent Expense Supplemental,2021-03-31 00:00:00,110000000.0,PPLPHARMA.NS
Diluted Average Shares,2021-03-31 00:00:00,,PPLPHARMA.NS
Basic Average Shares,2021-03-31 00:00:00,,PPLPHARMA.NS
Diluted EPS,2021-03-31 00:00:00,,PPLPHARMA.NS
Basic EPS,2021-03-31 00:00:00,,PPLPHARMA.NS
Diluted NI Availto Com Stockholders,2021-03-31 00:00:00,,PPLPHARMA.NS
Net Income Common Stockholders,2021-03-31 00:00:00,,PPLPHARMA.NS
Otherunder Preferred Stock Dividend,2021-03-31 00:00:00,,PPLPHARMA.NS
Net Income,2021-03-31 00:00:00,,PPLPHARMA.NS
Minority Interests,2021-03-31 00:00:00,,PPLPHARMA.NS
Net Income Including Noncontrolling Interests,2021-03-31 00:00:00,,PPLPHARMA.NS
Net Income Continuous Operations,2021-03-31 00:00:00,,PPLPHARMA.NS
Tax Provision,2021-03-31 00:00:00,,PPLPHARMA.NS
Pretax Income,2021-03-31 00:00:00,,PPLPHARMA.NS
Other Non Operating Income Expenses,2021-03-31 00:00:00,,PPLPHARMA.NS
Special Income Charges,2021-03-31 00:00:00,,PPLPHARMA.NS
Other Special Charges,2021-03-31 00:00:00,54100000.0,PPLPHARMA.NS
Write Off,2021-03-31 00:00:00,,PPLPHARMA.NS
Impairment Of Capital Assets,2021-03-31 00:00:00,374300000.0,PPLPHARMA.NS
Restructuring And Mergern Acquisition,2021-03-31 00:00:00,451900000.0,PPLPHARMA.NS
Net Non Operating Interest Income Expense,2021-03-31 00:00:00,,PPLPHARMA.NS
Total Other Finance Cost,2021-03-31 00:00:00,47100000.0,PPLPHARMA.NS
Interest Expense Non Operating,2021-03-31 00:00:00,,PPLPHARMA.NS
Interest Income Non Operating,2021-03-31 00:00:00,207000000.0,PPLPHARMA.NS
Operating Income,2021-03-31 00:00:00,,PPLPHARMA.NS
Operating Expense,2021-03-31 00:00:00,,PPLPHARMA.NS
Other Operating Expenses,2021-03-31 00:00:00,,PPLPHARMA.NS
Depreciation And Amortization In Income Statement,2021-03-31 00:00:00,,PPLPHARMA.NS
Depreciation Income Statement,2021-03-31 00:00:00,,PPLPHARMA.NS
Research And Development,2021-03-31 00:00:00,691400000.0,PPLPHARMA.NS
Selling General And Administration,2021-03-31 00:00:00,1837300000.0,PPLPHARMA.NS
Selling And Marketing Expense,2021-03-31 00:00:00,1298800000.0,PPLPHARMA.NS
General And Administrative Expense,2021-03-31 00:00:00,538500000.0,PPLPHARMA.NS
Rent And Landing Fees,2021-03-31 00:00:00,110000000.0,PPLPHARMA.NS
Gross Profit,2021-03-31 00:00:00,,PPLPHARMA.NS
Cost Of Revenue,2021-03-31 00:00:00,,PPLPHARMA.NS
Total Revenue,2021-03-31 00:00:00,,PPLPHARMA.NS
Operating Revenue,2021-03-31 00:00:00,,PPLPHARMA.NS
